Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluconazole
Drug ID BADD_D00912
Description Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.[A174325]
Indications and Usage For the treatment of fungal infections.
Marketing Status Prescription; Discontinued
ATC Code D01AC15; J02AC01
DrugBank ID DB00196
KEGG ID D00322
MeSH ID D015725
PubChem ID 3365
TTD Drug ID D09LNI
NDC Product Code 51407-424; 55111-144; 51407-301; 53104-7569; 70934-783; 70985-015; 16571-210; 68071-2557; 63187-584; 63275-9960; 68071-2347; 65862-059; 50090-0869; 51686-0006; 66039-857; 63629-8970; 67405-601; 70710-1137; 16714-691; 0395-8036; 55700-945; 51407-299; 51407-302; 55154-3400; 51407-300; 53002-4198; 65862-060; 51407-425; 57237-003; 50090-4426; 51407-426; 68071-4651; 62559-990; 68462-104; 0172-5412; 0172-5410; 72189-143; 63187-096; 0143-9668; 63629-1950; 16571-211; 50090-3899; 68071-4002; 43063-642; 68071-4501; 55289-148; 71335-1268; 71335-0686; 51672-4066; 52343-087; 68071-2436; 71205-563; 70771-1065; 52343-085; 51672-4065; 50090-4425; 0049-3410; 63629-1948; 0904-6500; 38779-2442; 71335-1037; 70710-1140; 50090-2195; 55111-145; 59762-5018; 68071-2609; 57237-149; 52343-086; 71205-081; 70985-016; 16571-212; 61919-380; 51927-3783; 0049-3450; 70518-0560; 62559-993; 25021-184; 52343-088; 72789-209; 72189-149; 76420-164; 50090-5299; 70710-1138; 60760-804; 16714-696; 70518-3312; 0143-9669; 70934-935; 16714-692; 50268-339; 65862-299; 51672-4067; 71335-1511; 63629-1947; 0049-3440; 0338-6045; 50090-3194; 68084-728; 64567-0002; 59762-5017; 67405-604; 70771-1063; 65862-300; 68071-2601; 49452-3149; 59762-5016; 65427-025; 59762-5015; 72189-140; 61919-419; 57237-006; 72789-096; 51552-1031; 67405-603; 55111-039; 0904-6501; 53069-0380; 71335-0557; 60760-803; 0338-6046; 50090-4864; 65015-601; 70985-013; 62559-992; 71335-1954; 59762-5029; 70710-1139; 16714-693; 0049-3420; 71335-0764; 68788-7959; 70518-2415; 71335-1175; 68001-253; 0143-9666; 51655-435; 63629-8971; 71335-1895; 53002-4400; 63629-9091; 53002-2198; 70518-2411; 62559-991; 55111-146; 71335-1448; 65841-108; 71205-573; 68001-252; 71205-104; 51672-4064; 72189-342; 43063-645; 51407-427; 16714-695; 59762-5030; 70934-501; 71335-1948; 68462-102; 63629-7986; 55111-143; 0172-5411; 60592-209; 57237-150; 70518-3092; 62991-2651; 65862-058; 16571-213; 63187-878; 0143-9667; 67405-602; 55154-7875; 65862-061; 68462-119; 0172-5413; 63629-8749; 57237-004; 62207-008; 68788-7150; 0049-3430; 71205-283; 70985-014; 71335-0769; 70518-2087; 63629-1949; 43063-326; 0143-9899; 0049-3500; 68084-735; 68071-4386; 70771-1066; 61919-493; 71205-650; 50268-337; 70518-3111; 68001-251; 60760-113; 55700-916; 61919-333; 68788-7621; 50090-5764; 57237-005; 53104-7522; 68788-7293; 68001-254; 65862-297; 63187-613; 70771-1064; 16714-694; 53002-1198; 63629-9134; 50090-3196; 70518-3100; 55700-521; 68788-7888; 55289-824; 68462-101; 71205-094; 13371-418
Synonyms Fluconazole | Zonal | Béagyne | Diflucan | Fluc Hexal | Flucobeta | FlucoLich | Fluconazol AbZ | Fluconazol AL | Fluconazol Stada | Fluconazol von ct | Fluconazol-Isis | Fluconazol Isis | Fluconazol-ratiopharm | Fluconazol ratiopharm | Flunazul | Fungata | Lavisa | Loitin | Neofomiral | Oxifungol | Solacap | UK-49858 | UK 49858 | UK49858 | Triflucan | Apo-Fluconazole | Apo Fluconazole
Chemical Information
Molecular Formula C13H12F2N6O
CAS Registry Number 86386-73-4
SMILES C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HypersensitivityATP-dependent translocase ABCB1P08183T252589797228; 12019078; 11864952; 10390213
HypersensitivityLanosterol 14-alpha demethylaseQ8K0C4Not Available9797228; 12019078; 11864952; 10390213
HypersensitivityATP-dependent bile acid permeaseP32386Not Available9797228; 12019078; 11864952; 10390213
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Toxic neuropathy17.09.03.017; 12.03.01.0550.000206%Not Available
Vulvovaginal pain21.08.02.0090.000309%
Kounis syndrome02.02.02.020; 24.04.04.020; 10.01.03.0370.000516%Not Available
Acute kidney injury20.01.03.016--
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000377%Not Available
White matter lesion24.04.06.027; 17.11.01.0090.000206%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.001547%Not Available
Diffuse alopecia23.02.02.0070.000412%Not Available
Developmental hip dysplasia15.11.07.014; 03.11.07.0140.000206%Not Available
Candida infection11.03.03.0210.000215%
Aspergillus infection11.03.01.0040.000081%Not Available
Immune thrombocytopenic purpura10.04.01.008; 01.08.01.0070.000206%Not Available
Body temperature abnormal13.15.01.0300.000206%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000215%
Abdominal mass07.01.01.0030.000206%Not Available
Abnormal loss of weight14.03.02.0190.000206%Not Available
Blood blister23.03.01.028; 12.01.06.0130.000309%Not Available
Blood corticosterone increased13.10.09.0100.000516%Not Available
Disseminated cryptococcosis11.03.04.0040.000309%Not Available
Lymphadenopathy mediastinal22.09.03.006; 01.09.01.0250.000206%Not Available
Peripheral T-cell lymphoma unspecified16.17.06.001; 01.11.06.0010.000054%Not Available
Pleocytosis17.02.05.0590.000206%Not Available
Pulmonary valve stenosis congenital03.07.05.016; 02.07.04.0060.000516%Not Available
Transposition of the great vessels24.03.03.042; 03.07.08.009; 02.08.03.0050.000619%Not Available
Tumour marker increased13.22.01.0170.000412%Not Available
Pulmonary cavitation22.01.02.0220.000206%Not Available
Acinetobacter infection11.02.01.0330.000054%Not Available
Genital erythema23.03.06.019; 21.10.01.0150.000412%Not Available
Palatal oedema07.05.04.0080.001031%Not Available
Mycotic endophthalmitis11.03.05.025; 06.04.05.0290.000206%Not Available
The 14th Page    First    Pre   14 15    Next   Last    Total 15 Pages